Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

拨康视云™
Cloudbreak Pharma

CLOUDBREAK PHARMA INC.

撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The board (the "**Board**") of directors (the "**Directors**") of Cloudbreak Pharma Inc. (the "**Company**") hereby announces that the principal place of business of the Company in Hong Kong has been changed to Suite 2006, 20th Floor, Tower 1, The Gateway, Harbour City, Kowloon, Hong Kong, with effect from 13 November 2026.

Continued Suspension of Trading

All dealings in the shares of the Company have been suspended by The Stock Exchange of Hong Kong Limited as directed by the Securities and Futures Commission since 9:00 a.m. on 10 September 2026 and will remain suspended until further notice.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
Cloudbreak Pharma Inc.
Dr. NI Jinsong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 13 November 2026

As at the date of this announcement, the Board comprises: (i) Dr. Ni Jinsong, Mr. Dinh Son Van and Dr. Yang Rong as executive Directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive Directors; and (iii) Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter, Mr. Lee Alex Jao Jang, Mr. Chan Sheung Yan Andrew and Mr. Kwai Sze-kit Gavin as independent non-executive Directors.

* *For identification purpose only*